Skip to main content

Table 3 Combination indices in drug combination studies of irinotecan and the multi-kinase inhibitors sorafenib and sunitinib

From: Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

Inhibitor, CI BT 12 BT 16 KCCF1
Sorafenib 0.7 0.8 0.9
Sunitinib 0.9 0.3 0.4